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Abstract
Background:  Meningococcal disease can have devastating consequences. As new vaccines
emerge, it is necessary to assess their impact on public health. In the absence of long-term real
world data, modeling the effects of different vaccination strategies is required. Discrete event
simulation provides a flexible platform with which to conduct such evaluations.
Methods: A discrete event simulation of the epidemiology of invasive meningococcal disease was
developed to quantify the potential impact of implementing routine vaccination of adolescents in
the United States with a quadrivalent conjugate vaccine protecting against serogroups A, C, Y, and
W-135. The impact of vaccination is assessed including both the direct effects on individuals
vaccinated and the indirect effects resulting from herd immunity. The simulation integrates a variety
of epidemiologic and demographic data, with core information on the incidence of invasive
meningococcal disease and outbreak frequency derived from data available through the Centers for
Disease Control and Prevention. Simulation of the potential indirect benefits of vaccination
resulting from herd immunity draw on data from the United Kingdom, where routine vaccination
with a conjugate vaccine has been in place for a number of years. Cases of disease are modeled
along with their health consequences, as are the occurrence of disease outbreaks.
Results: When run without a strategy of routine immunization, the simulation accurately predicts
the age-specific incidence of invasive meningococcal disease and the site-specific frequency of
outbreaks in the Unite States. 2,807 cases are predicted annually, resulting in over 14,000 potential
life years lost due to invasive disease. In base case analyses of routine vaccination, life years lost due
to infection are reduced by over 45% (to 7,600) when routinely vaccinating adolescents 12 years
of age at 70% coverage. Sensitivity analyses indicate that herd immunity plays an important role
when this population is targeted for vaccination. While 1,100 cases are avoided annually when herd
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immunity effects are included, in the absence of any herd immunity, the number of cases avoided
with routine vaccination falls to 380 annually. The duration of vaccine protection also strongly
influences results.
Conclusion: In the absence of appropriate real world data on outcomes associated with large-
scale vaccination programs, decisions on optimal immunization strategies can be aided by discrete
events simulations such as the one described here. Given the importance of herd immunity on
outcomes associated with routine vaccination, published estimates of the economic efficiency of
routine vaccination with a quadrivalent conjugate vaccine in the United States may have
considerably underestimated the benefits associated with a policy of routine immunization of
adolescents.
Background
Invasive meningococcal disease, although relatively rare,
can have devastating consequences, with case-fatality rates
over 10% [1-3] and rates of permanent sequelae amongst
survivors, including neurological complications, limb
loss, mental retardation, hearing loss, renal failure and
paralysis in up to 20% of reported cases [2-5].
Most cases of meningitis in industrialized countries are
due to endemic disease. In the US, for example, endemic
cases make up approximately 97% of cases [1]. Neverthe-
less, sporadic outbreaks occur [1,6], often leading to con-
siderable anxiety in the affected population and to costly
outbreak control measures. Between 1994 and 2002,
there were approximately 75 outbreaks across the US [6].
The overall incidence of meningococcal disease varied
from year to year, but was roughly 1 to 2 cases per 100 000
individuals per year, with the great majority of cases due
to serogroups B, C, Y and W-135 [1]. Serogroup A disease,
though more common in the past, is now relatively rare in
industrialized countries [1].
Until recently, routine vaccination for meningococcal dis-
ease had not been recommended in the US, except for
individuals entering college [7], but vaccination during
outbreaks was common [6]. A quadrivalent polysaccha-
ride vaccine, protective against serogroups A, C, Y and W-
135 had been the only vaccine used. That vaccine, how-
ever, has relatively poor efficacy in younger children and
does not provide long-lasting protection [8]. There have
also been suggestions that the effectiveness of polysaccha-
ride meningococcal vaccines against colonization may be
weak and short-lived [9]. New conjugate vaccines are
expected to offer better protection [8,9] and may also
reduce carriage of meningococci [10], allowing for the
possibility of indirect benefits of vaccination brought
about by herd immunity [11] In the UK, routine vaccina-
tion of children with a conjugate C vaccine has been
implemented and has been successful [10-12] 11. Menac-
tra®, a quadrivalent conjugate vaccine was approved for
use in the US in early 2005, and the Centre for Disease
Control's Advisory Committee on Immunization Prac-
tices has now recommended routine vaccination of young
adolescents and college students [13].
Given the relatively low incidence of disease, a means of
assessing outcomes under various vaccination strategies is
necessary for stakeholders to make informed decisions on
vaccinating with the newer, more effective vaccines. While
a number of epidemiological and health economic mod-
els of varying complexity have been developed [14-23],
we propose a new approach to the modelling of meningo-
coccal disease: an individual person model using discrete
event simulation techniques [24,25].
The simulation presented here was designed to provide
decision makers with insight into the direct effects of
immunization in vaccinated individuals and the potential
indirect effects, often referred to as herd immunity, result-
ing from reduced transmission, both in terms of incidence
and of outbreaks. In the United States, economic evalua-
tions of vaccination for meningococcal vaccine have
focused exclusively on the direct effects of immunization
on vaccinated individuals [19,26,27]. This narrow focus
could mean that these evaluations, regardless of the qual-
ity of their economic data, significantly underestimate the
benefits and cost offsets from reduced disease resulting
from routine vaccination. Although there remain signifi-
cant data gaps, one of the goals in developing this simula-
tion was to assess the impact of herd immunity on the
incidence of disease and to guide future research by allow-
ing for evaluation of the importance of key epidemiologic
inputs and assumptions. To our knowledge, previous
models have not attempted to capture the population-
wide direct and indirect effects of vaccination on both
incidence of disease and on outbreaks.
This paper provides a detailed description of the discrete
event simulation developed to evaluate the epidemiology
of invasive meningococcal disease in the United States,
and the resulting predictions of the potential impact of
routinely vaccinating adolescents with a quadrivalent
conjugate vaccine. As the simulation presented here uses
a novel approach to modelling meningococcal disease,BMC Public Health 2007, 7:130 http://www.biomedcentral.com/1471-2458/7/130
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and is the first to assess the impact of the direct and indi-
rect effects of vaccination on disease incidence as well as
the occurrence and extent of meningitis outbreaks, testing
the validity and robustness of results is vital. As such, after
describing the model's structure and the vaccination strat-
egies considered, we detail the method used for testing its
robustness and ensuring its validity.
Methods
The model simulates the experience of dynamic commu-
nities of individuals over a specified time horizon and
under various epidemiological conditions. In this paper,
we simulate US communities with starting populations of
200,000 individuals. Reported results are scaled up to
reflect outcomes for the entire US population. Epidemio-
logical, demographic, and health utility data used to pop-
ulate the simulation are detailed in Appendix 1.
Each simulated community consists of a number of pri-
mary schools, high schools and one college. Schools are
included in the analysis as epidemiological evidence
[7,28,29] indicates that they are a common location for
clusters of disease. Individuals are assigned specific char-
acteristics such as age, gender and educational status and
the evolution of their status regarding meningococcal dis-
ease and vaccination is tracked on a daily basis (Figure 1).
When a case occurs, the health effects, and impact on
quality of life are calculated over the lifetime of the
infected individual. At the same time, school-contacts and
household contacts for that case are identified according
to the distribution of household and school sizes in the
community. These contacts are then exposed for a limited
period of time to an increased risk of developing menin-
gococcal disease.
The model determines whether an outbreak, either in the
community or in a specific school, is declared. Outbreaks
are defined on the basis of the number of cases of the
same serogroup occurring within a three-month period:
two or more in the same school for school outbreaks or
ten or more per 100,000 individuals for community out-
breaks [6,30]. In order to avoid double counting, school
outbreaks occurring during a community outbreak, were
considered to be part of the community outbreak. If an
outbreak is triggered in the simulation each individual
may be vaccinated as a result of outbreak control interven-
tions by public health authorities.
Given the complex nature of outbreaks [31,32], we intro-
duce high-risk periods at a rate calibrated to fit observed
outbreak data in terms of frequency, serogroup distribu-
tion and scale (i.e., community or school outbreak). Dur-
ing these periods, all individuals are exposed to a risk of
infection that is higher than the baseline endemic risk.
Details of the method used to integrate these high-risk
periods into the simulation are provided in Appendix 2.
In addition to vaccination during outbreaks, the model
allows for the introduction of routine vaccination for
specified subgroups of the population. When individuals
are vaccinated, either through a routine vaccination pro-
gram or as a result of outbreak control measures, they
attain a degree of protection against invasive meningococ-
cal disease for a defined period of time. The number of
individuals vaccinated and directly protected against car-
riage of Neisseria meningitidis can also affect the overall
risk for the entire population.
To estimate the impact of vaccination on Neisseria menin-
gitidis  transmission, we assumed that the vaccine used
would be the one currently licensed for use in the US: a
conjugate meningococcal vaccine protecting against sero-
types A, C, Y and W-135. In the absence of long-term effi-
cacy data for this vaccine, we extrapolated long-term
protection from UK effectiveness data [12] for a C conju-
gate meningococcal vaccine and assumed that the quadri-
valent vaccine was equally effective against all serogroups.
The mean duration of direct protection against meningo-
coccal infection under these assumptions is 30.1 years
(Figure 2).
The meningococcal C vaccination campaign in the UK
[11] demonstrated that benefits accrue not only to vacci-
nated individuals, but also to the entire population. In
order to capture these indirect effects, we assumed that
vaccinating individuals with a conjugate vaccine decreases
the probability that they are carriers and can transmit the
Schematic representation of the simulation Figure 1
Schematic representation of the simulation. Individuals are 
created and follow the flow-chart on a daily basis.BMC Public Health 2007, 7:130 http://www.biomedcentral.com/1471-2458/7/130
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disease. Consistent with a recent epidemiological model
of the impact of meningococcal vaccination in the UK
[20], individuals in the same age group were assumed to
mix more frequently than individuals across age groups.
Inputs were calibrated to reproduce the outcome observed
in the UK that with vaccination of 81% of individuals
under the age of 20 years, disease incidence fell by 67% in
unvaccinated individuals in the same age group and 35%
in adults [11]. The method used for calculating indirect
effects is described in greater detail in Appendix 2.
Simulation settings
Analyses are run for routine vaccination with a quadriva-
lent conjugate vaccine of 12-year olds and compared to
simulations with no routine vaccination. The analyses
assume 71% coverage amongst 12 years olds [19] attained
in the first year of the program and maintained through-
out its duration.
In both strategies, outbreaks of disease due to vaccine-pre-
ventable serogroups are assumed to lead to outbreak
immunization campaigns. For outbreaks in primary and
secondary schools, 100% coverage iss assumed, while for
those in colleges, 90% is used. For community-based out-
breaks, the coverage is set at 90% for children and adoles-
cents and 70% for those of college age [33,34].
Simulations are run over a 100 year time horizon, but
results are presented for years when all people between
the ages of 12 and 100 years have either been vaccinated
or were eligible for vaccination as part of a routine vacci-
nation program – that is, when maximum vaccine pene-
tration has been reached (referred to as steady state).
Sensitivity analyses
The novelty of the model presented creates a need for test-
ing its validity and robustness. In terms of validity, the
best approach would be to run the model with data
observed in a given setting or community and then testing
whether the model is able to reproduce data observed in
another setting or community The nature of data availa-
ble, however, makes such an approach unfeasible. In
order to ensure that the model reproduce correctly what is
known about transmission of meningococcal disease and
outbreaks, we developed calibration procedures aimed at
reproducing at best available data for the three key vacci-
nation-related parameters in the model: duration of vac-
cine protection, indirect effects of vaccination, and
outbreak occurrence and scale. These calibration proce-
dures are detailed in Appendix 2.
Testing the robustness of simulated findings is driven by
the identification of key parameters of influence. This was
accomplished by performing sensitivity analyses on dif-
ferent features and input data of the model. These analy-
ses were performed on population size, relative risk of
contracting the disease when coming into contact with an
active case, herd immunity, vaccine efficacy, vaccine cov-
erage rates, and baseline incidence.
We assessed the contribution of the relative risk in contact
contacts by running analyses with no increased risk to
contacts, and doubling the baseline relative risk in con-
tacts. The impact of herd immunity was varied from 0%
(no herd immunity) to 150% (50% greater indirect effect
compared to base case). The rate of waning for vaccine
efficacy was doubled and halved leading to an estimated
average duration of direct protection from vaccination of
between 15 and 60 years. Coverage rates for routine vacci-
nation were varied from 50% to 90% for routine vaccina-
tion, and baseline incidence was varied by 25% in either
direction. Finally, the impact of the size of the community
on model predictions was tested by considering a larger
community size than used in the base case (500,000 indi-
viduals instead of 200,000). For this parameter, however,
we proceeded differently than for the other sensitivity
analyses, as a specific calibration procedure on the out-
break rate was performed. Given that the community size
parameter is somewhat arbitrary, it is important that the
impact of the variable be controlled by recalibrated
parameter values.
Results
In the absence of routine vaccination, the simulation
closely reproduces the incidence of disease and outbreaks
observed in the US, with an estimated 2,807 cases per
year, 375 of which are fatal and 471 lead to permanent
disability (Table 1). This leads to a loss of more than
14,000 life years and of almost 17,000 quality adjusted
Estimated effectiveness of vaccination with conjugate menin- gococcal disease vaccine over time Figure 2
Estimated effectiveness of vaccination with conjugate menin-
gococcal disease vaccine over time.
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life years (QALYs). Predictions on incidence, deaths
related to meningococcal disease, and outbreaks accu-
rately reproduce the known epidemiology of meningo-
coccal disease in the US in the years prior to the
recommendation to routinely vaccinate adolescents.
Routine vaccination of 12 year olds quickly leads to a sub-
stantial reduction in the number of cases of meningococ-
cal disease. Assuming immediate coverage of 71%, the
incidence of vaccine-preventable disease falls by 35% after
10 years, from 0.62 to 0.41 per 100,000 person years (Fig-
ure 3). With routine vaccination simulations indicate a
marked drop in cases amongst targeted age groups (Figure
4), but benefits decrease as vaccinated individuals age and
protection conferred through immunization wanes. Fig-
ure 4 also illustrates the indirect benefits of vaccination, as
evidenced by the gap that opens up with routine vaccina-
tion across all age groups, including in those younger than
12 years. Direct benefits of vaccination obviously result in
no change in incidence below the age of 12, and a much
smaller decline in adult cases.
By steady state, routine vaccination of 12 year olds reduces
the average annual number of cases by over 1,000, a
decrease of 39% in all cases and 62% in vaccine-prevent-
able cases (Table 1). There are 189 fewer deaths and 190
fewer cases resulting in permanent disability, leading to a
46% reduction in life years lost (from 14,151 to 7,616),
and 43% reduction in QALYs lost (from 16,852 to 9,626).
Under base case assumptions, just over 2,500 individuals
would need to be vaccinated to avoid a case, and almost
15,000 to avoid one death due to meningococcal disease.
In addition to a reduction in the number of cases, the sim-
ulation predicts a 74% lower occurrence of outbreaks with
routine vaccination (from 9.1 to 2.4), and 97% fewer out-
breaks caused by vaccine-preventable serogroups (from
6.9 to 0.2).
Sensitivity analyses
Results presented in Figures 5 and 6 allow for identifica-
tion of those parameters that have a strong influence on
the predicted impact of vaccination using the simulation.
Not surprisingly, both the direct effects of vaccination
(vaccine efficacy) and the indirect effects (herd immunity)
have a strong impact on both the number of cases and on
the number of outbreaks prevented by vaccination. With-
out herd immunity, the number of cases avoided with
routine immunization drops avoided from 1,100 per year
to 380 per year. The number of outbreaks prevented falls
from 6.7 to about 5. Reducing the duration of the protec-
tion conferred by the vaccine by 50% (low vaccine effi-
cacy) leads to a reduction in cases compared to no routine
Table 1: Steady state summary results from simulations comparing routine vaccination of 12-year-olds to no routine vaccination, 
under base case assumptions and for sensitivity analyses on coverage rates, low vaccine efficacy (doubling waning of vaccine 
effectiveness) and halving herd immunity
No 
Vaccination
Base case 
(71% coverage)
90% 
coverage
50% 
coverage
Low Vaccine 
efficacy
Low Herd 
Immunity
Total Cases 2,806.7 1,716.9 1,500.6 1,969.2 2,121.6 2,056.2
Secondary Cases 45.5 15.5 14.1 18.0 19.0 20.4
Serogroup A 8.7 2.3 1.76 2.4 4.4 3.31
Serogroup B 839.6 843.4 836.9 837.4 823.5 843.2
Serogroup C 748.5 281.7 194.8 387.1 461.1 437.1
Serogroup Y 773.7 305.9 212.5 420.3 492.9 445.4
Serogroup W-135 247.9 90.5 62.5 129.3 152.6 137.5
Other Serogroups 188.3 193.11 192.1 192.7 187.2 189.6
Fatal Cases 375.0 186.4 147.7 233.8 268.1 250.1
Cases with Disability 471.4 281.6 243.39 325.9 355.4 340.8
Life Years Lost 14,151.1 7,616.0 6,352.7 9,143.0 10,112.8 9,640.9
QALYs Lost 16,852.1 9,626.2 8,234.8 11,287.5 12,281.4 11,834.9
Total Outbreaks 9.1 2.4 2.2 2.8 2.8 2.9
Outbreak Cases 91.2 24.9 23.7 26.4 27.3 27.0
Community Outbreaks 2.9 0.7 0.7 0.7 0.8 0.8
Serogroup B 2.2 2.2 2.2 2.2 2.2 2.2
Serogroup C 5.8 0.2 <0.1 0.57 0.57 0.64
Serogroup Y 1.1 <0.1 0.0 <0.1 <0.1 0.1
Other Serogroups 0.0 0.0 0.0 0.0 0.0 0.0
Number Vaccinated 119,171 2,866,522 3,634,838 2,020,350 2,867,463 2,867,233
During Outbreak 119,171 137 37 594 1,078 848
Cases Averted due to Routine Vaccination -1,090 -1,306 -837 -685 -743
Death Averted due to Routine Vaccination -189 -227 -141 -107 -123
Number Needed to Vaccinate to Avoid One Case 2,521 2,692 2,271 4,012 3,699
Number Needed to Vaccinate to Avoid One Death 14,536 15,488 13,484 25,685 22,342BMC Public Health 2007, 7:130 http://www.biomedcentral.com/1471-2458/7/130
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vaccination of 24%. Using the base case estimate of dura-
tion of protection, a 39% reduction is predicted. The
impact of the high (90%) and low (50%) vaccination cov-
erage rates also influence predictions, but not nearly as
great as when direct and indirect effectiveness of the vac-
cine is considered. Table 1 provides more detailed results
on outcomes when varying coverage rates, and reducing
the direct and indirect effectiveness of the vaccine.
Other parameters have a much more limited influence on
predictions. Varying incidence changes absolute number
of cases with (2,124 versus 1,717 in the base case) and
without (3,517 versus 2,807 in the base case) routine vac-
cination but has a relatively small effect on net outcomes.
Similarly, although modification of the relative risk of
exposed contacts has a large effect on the frequency of out-
breaks in the absence of vaccination (+62% for the high
relative risk scenario and -90% for the no increased risk
scenario), the percent reduction in outbreaks resulting
from vaccination changes very little.
After calibration for outbreak related parameters, analyses
using a larger community size indicate that this parameter
has only a very limited influence on the reduction of cases
and outbreaks. It should be noted, however, that calibra-
tion of outbreak related parameters limit the potential
influence of changes in community size. Analyses indicate
that increasing the size of communities to 500,000 indi-
viduals results in small differences not only in the reduc-
tion of cases and outbreaks resulting from vaccination,
but also on the absolute number of cases across the US
(1,724 cases with routine vaccination versus 1,717 cases
with routine vaccination in the base case).
Cases avoided per year with routine vaccination of adoles- cents under different scenarios at steady state Figure 5
Cases avoided per year with routine vaccination of 
adolescents under different scenarios at steady state. 
Larger community size – 500,000 individuals. No/high con-
tact relative risk – 0%/200% of base case relative risk. Low/
high incidence – 75%/125% of base case incidence. Low/high 
vaccine efficacy – doubling/cutting in half the rate of decay for 
vaccine effectiveness. No/Low/High herd immunity – 0%/
50%/150% of base case herd immunity. 50%/90% coverage – 
coverage rate for routine vaccination.
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Incidence of meningococcal disease (total and vaccine pre- ventable) over 100 years following initiation of routine vacci- nation of 12 year olds Figure 3
Incidence of meningococcal disease (total and vaccine pre-
ventable) over 100 years following initiation of routine vacci-
nation of 12 year olds.
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Discussion
Results from the simulations suggest that routine immu-
nization of an adequately large subset of the population
with an effective quadrivalent vaccine can lead to substan-
tial reductions in cases of disease. Furthermore, the indi-
rect benefits associated with herd immunity seem to be
just as important as the direct benefits conferred upon
vaccinees.
Under base case assumptions, routine immunization of
12 year olds in the US is predicted to reduce the incidence
of invasive disease by almost 40%, and vaccine-preventa-
ble disease by over 60%. Outbreaks of invasive meningo-
coccal disease from serogroups A, C, Y, and W-135 are all
but eliminated. Sensitivity analyses clearly demonstrate
the importance of herd immunity and duration of immu-
nity after vaccination in determining the long-term
impact of routine vaccination policies.
By providing a framework for the evaluation of strategies
to control invasive meningococcal disease which takes
into consideration the direct and indirect benefits of
immunization, the short and long-term consequences of
the disease, and the impact of outbreaks at both the insti-
tutional and community level, the simulation developed
for these analyses provides a more complete description
of the potential impact of meningococcal vaccination
than the simpler cohort models used in the past to evalu-
ate the economic efficiency of routine vaccination in the
US for meningococcal disease [19,26,27]. An important
next step using the results of these simulations will be to
incorporate cost and resource use data on managing infec-
tions, vaccination activities and outbreak control, in order
to re-evaluate the cost-effectiveness of instituting routine
vaccination of 12 year olds. Given that benefits resulting
from herd immunity and outbreak frequency reduction
were not considered in the most recent estimate put forth
by the CDC [19], one would expect that the cost-effective-
ness of routine vaccination of US adolescents with a quad-
rivalent conjugate vaccine would be considerably lower
than their ratio of $121,000 per life year gained.
Modelling the epidemiology of infectious diseases can be
complex, but is necessary for reasonable evaluation of
infection control strategies [25]. Although still relatively
uncommon in epidemiology, discrete event simulations
are increasingly used; a recent example being an assess-
ment of smallpox management strategies in the US [35].
Discrete event simulation is a useful technique when
modelling interaction between individuals in a popula-
tion. The simulation is specified and run at the level of the
individual, with each person assigned specific characteris-
tics which are carried in the model and updated periodi-
cally. This simulation technique also allows the events
occurring in individuals to influence outcomes in other
individuals, by specifying interaction between them and
the consequences of this interaction [24].
As with any model, one of the main challenges rests with
limited data availability. Often, available data alone are
not sufficient, requiring calibration procedures to be per-
formed in order to ensure that the model best represents
what is known about the disease and its prevention. In the
simulation described here, calibration was necessary for
three key parameters: duration of protection, herd immu-
nity and outbreak risks.
Recently published models in this area have varied greatly
in terms of sophistication and scope, ranging from simple
deterministic models that ignore the indirect effects of
vaccination or incorporate them by brute force [15-
17,19,22] 16, to more sophisticated dynamic transmis-
sion and stochastic mathematical models [18,20,21,23].
The latter have demonstrated the importance of taking the
indirect effects of vaccination into consideration. For
example, an economic evaluation of use of a conjugate C
meningococcal vaccine in the UK using a dynamic age-
structured transmission model estimated that cases
avoided due to the indirect effects of vaccination were
more than three times greater than the direct effect [23], a
finding in agreement with our results for the US. Recent
models have also highlighted the importance of outbreaks
Outbreaks avoided per year with routine vaccination under  different scenarios at steady state Figure 6
Outbreaks avoided per year with routine vaccination 
under different scenarios at steady state. Larger com-
munity size – 500,000 individuals. No/high contact relative 
risk – 0%/200% of base case relative risk. Low/high incidence 
– 75%/125% of base case incidence. Low/high vaccine efficacy 
– doubling/cutting in half the rate of decay for vaccine effec-
tiveness. No/Low/High herd immunity – 0%/50%/150% of 
base case herd immunity. 50%/90% coverage – coverage rate 
for routine vaccination.
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[19,21], but none have evaluated the effect of vaccination
on outbreaks. Although uncommon, outbreaks are a sig-
nificant public health concern given the serious conse-
quences and the fear generated in affected communities.
The simulation described in this paper incorporates real-
world data into a framework that allows for evaluation of
both the direct and indirect benefits of vaccination,
including the effects on outbreaks.
The model does have limitations that should be taken
into consideration. Although not a limitation of the
model per se, this simulation deals only indirectly with
the relationship between carriage and invasive disease
because the required data are lacking. We opted to include
it anyway given its importance and calibrated the inputs
to the observed herd immunity effects of the serogroup C
vaccination campaign in the UK [11]. This simplified
approach allows for a clear and relatively straightforward
testing of assumptions but caution should be exercised in
interpreting results as a linear relation is assumed between
direct vaccine protection in the community and the extent
of herd immunity for the same age group. For example, it
is almost surely the case that changing coverage from 10%
to 20% versus 70% to 80% will not have the same effect
on herd immunity. Furthermore, the strength of the rela-
tionship between vaccine protection and coverage was
estimated based on the experience of a single large-scale
vaccination program [11]. While herd immunity with vac-
cination seems to have taken place with other vaccination
programs, other factors not considered by the simulation
may come into play in determining the indirect benefits of
vaccination. The effect of vaccination on carriage, and as a
consequence on herd immunity, was dealt with conserva-
tively by assuming a shorter duration of protection against
carriage than against the disease, and sensitivity analyses
evaluated the impact of different assumptions.
By the same token, the incidence of outbreaks is forced,
with calibration to existing data. The impact of vaccina-
tion on the occurrence of these outbreaks can then be
taken into consideration, and sensitivity analyses can be
run under alternative assumptions on the frequency and
severity of high risk periods. The model does not take into
consideration what factors lead to outbreaks, such as the
appearance of more invasive strains of meningococcal dis-
ease.
Another limitation of the analyses presented here is the
assumption of uniform communities of equal size. In
reality, the epidemiology of disease may well vary by the
size of the community as well as by other community
characteristics. The sensitivity analyses run on community
size, however, are reassuring in that when calibration pro-
cedure account for changes in the size of the community,
only a limited impact on model predictions is observed.
Furthermore, uptake rates for both outbreak and routine
vaccination may vary from community to community.
With adequate data on inter-community migration pat-
terns, as well as the distribution and make-up of commu-
nities in a given region or country, the model could
handle differing communities and the effects of migra-
tion. Acquiring the data required for such analyses, how-
ever, would be a considerable undertaking. Furthermore,
the computing time required to model large numbers of
heterogeneous communities may be a deterrent. Uptake
of routine vaccination was also assumed to be immediate.
More gradual uptake would delay the time required to
reach steady state and achieve maximum benefits.
Finally, the model currently assumes that the overall
endemic risk of infection, outbreak frequency, and other
epidemiological characteristics of the disease are constant
over time. Again, while the model could incorporate lon-
gitudinal changes in these, we are not aware of any data
that would allow forecasting of these changes over time.
Despite these limitations, the model accurately replicates
the current incidence of disease and outbreaks in popula-
tions, and provides plausible ranges of estimates of out-
comes with routine vaccination of adolescents. The
simulation results also highlight the key role herd immu-
nity can play in determining outcomes, and the sensitivity
of predicted results to assumptions on the strength of herd
immunity, as well as the duration of vaccine effectiveness.
Conclusion
The development of new vaccines, such as Menactra, a
quadrivalent conjugate vaccine, and Menjugate, a conju-
gate C vaccine currently used for vaccination in countries
such as the UK and Canada, provide important opportu-
nities for reducing the burden of disease. Longer-term
data on the effectiveness of these vaccines, both in terms
of protection against disease and against carriage, will
allow for more precise estimates. In the absence of appro-
priate real world data on outcomes of large-scale vaccina-
tion programs, however, decisions on optimal
immunization strategies should be aided by tools such as
this discrete event simulation. Analytic frameworks that
ignore the indirect effects of vaccination resulting from
herd immunity may produce misleading results.
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Appendix 1 – simulation input data
General population characteristics
The age and gender distributions of individuals in each
community at the onset of the simulation were based on
overall US census data for the year 2000, as was the fertil-
ity rate used to calculate the number of births per year. All-
cause death hazards (Hazard = b•mAge) were derived from
2000 US life table data for all ages, except under the age of
one where the risk of death is much higher than predicted
using a Gompertz function. Thus, infant mortality was
taken directly from the life table.
The size of households (mean 2.6) was based on 2002 sta-
tistics from the US Census Bureau. For individuals under
the age of 18, it was assumed that at least one adult would
be residing in the same household.
The model assumes that all individuals of the appropriate
age attend primary school, and that all individuals begin
high school. Only 89.1% of individuals, however, com-
plete high school [36], and, for the sake of simplicity it is
assumed that all high school dropouts quit at the age of
15. Of those graduating from high school, 45% enroll in
college [36], and 63.4% of them are assumed to complete
their undergraduate degree [37]. Those not completing
their degree are assumed to leave college at the age of 20
years. Dormitories are assumed to be the place of resi-
dence for 26% of college freshmen and 12% of remaining
college students [7]. Data on the size of US schools were
taken from statistics provided by the US National Center
for Education Statistics [36].
Epidemiological data
Sero-specific risks of infection were calculated based on
data in the CDC's Active Bacterial Core Surveillance
(ABCs) reports for 1997 through 2001 [38] (Table 2). As
these reports did not identify rates for serogroups A and
W-135, data from the US for 1992 through 1996 [39] were
used to estimate that 54.8% of "Other" cases were group
W-135 disease, while only 2.1% were group A disease.
Weibull functions ( ) were fit to these data in
order to calculate the rate of invasive disease at any given
age (Table 3). A 3% reduction was applied to reflect that
the model uses them for endemic disease only [1,39]. Col-
lege students living in dormitories were subject to an
increased risk of infection (freshmen RR = 4.8, others 1.3)
[7].
The extent and duration (30 days) of increased risks of
household and school contacts (Table 4) were derived
from a UK study that examined clusters of meningococcal
disease in household and school settings between 1993
and 1995 [28]. Given no apparent increased risk in nurs-
ery school settings, these types of schools were not
included in the simulation. It was assumed that these rates
applied to a population with high rates of chemoprophy-
laxis in household contacts [28] and that contacts were
only at higher risk for disease caused by the same sero-
group as the primary case.
A case fatality rate of 12.3% was used in the simulation
based on data from the 1997 to 2001 ABCs reports. Data
from the literature supplemented this result in order to
develop serogroup [40] and age-specific [41] case fatality
rates. Rates of long-term sequelae for patients who do not
die from invasive disease were based on the literature
(20% in adults [5], 13.2% under the age of 18 [42]), with-
out sero-specificity (data were not available).
Health utilities
For the assessment of consequences related to meningitis
cases in the absence of long term sequelae, we use age-spe-
cific health utilities to calculate quality adjusted life years
(QALYs) which were based on reported EuroQOL scores
[43]. A regression equation was fit, such that
Health_Utility = 0.985337 - 0.000922 Age - 0.000031 Age2.
For adults with long-term sequelae, a loss of 26.25% in
health utility was reported [5]. For individuals under the
PA g e P
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Table 2: Average annual rates (per 100,000 individuals) of 
meningococcal disease in the US (1997–2001)
Age 
(years)
Group B Group C Group Y Other All 
Groups
<1 5.1 1.0 2.3 1.1 9.6
1 1.4 0.8 0.7 0.5 3.4
2–4 1.1 0.7 0.2 0.3 2.3
5–17 0.3 0.4 0.3 0.2 1.1
18–34 0.3 0.2 0.2 0.1 0.8
35–49 0.1 0.1 0.1 0.1 0.4
50–64 0.1 0.1 0.2 0.1 0.5
≥65 0.2 0.2 0.6 0.2 1.2
All Ages 0.3 0.2 0.3 0.1 1.0BMC Public Health 2007, 7:130 http://www.biomedcentral.com/1471-2458/7/130
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age of 18, types of complications were taken from a large
study on outcomes of invasive disease in children in Ire-
land from 1995 to 2000 [4], and combined with compli-
cation-matched utility losses for each complication [5,44-
46] for a resulting average utility loss of 28%. For cases
resulting in death or disability, outcomes are calculated
over the individual's expected lifetime had they not been
infected.
Appendix 2 – calibration procedures for key 
parameters
Outbreaks
In order to incorporate outbreaks in the model, high inci-
dence periods were introduced in the simulation. The cal-
ibration procedure consisted of determining the increase
in risk and the frequencies of high risk periods for each
serogroup that best reproduced the available data on out-
break frequency and size in the US [6].
Over an eight year period, there were 76 outbreaks of
meningococcal disease in the US, 48 of serogroup C dis-
ease, 19 of serogroup B disease, and 9 of serogroup Y dis-
ease. Of these, 26 were community-wide outbreaks, while
50 were limited to single institutions. Calibration to these
outcomes was conducted by first determining, for each
serogroup, what increase in risk would be required to lead
to the correct distribution of community versus school-
based outbreaks, assuming that 34% of outbreaks for all
serogroups are community outbreaks. The resulting risks
of infection during these high incidence periods, which
were assumed to last for three months. For serogroup B,
age-specific risks of infection were increased by a factor of
87.5; for serogroup C, by a factor of 118.5; and for sero-
group Y, by a factor of 97.9. The second step of the calibra-
tion procedure relates to the frequency of occurrence of
these high incidence periods, and resulted in annual prob-
abilities of 0.36% per community for serogroup B disease,
0.88% for serogroup C disease, and 0.34% for serogroup
Y disease.
Direct effects of vaccination
In the absence of long-term efficacy data for a conjugate
meningococcal vaccine protecting against serotypes A, C,
Y and W-135, we used UK effectiveness data [12] for a C
conjugate meningococcal vaccine and assumed that the
quadrivalent vaccine was equally effective against all sero-
groups. To extrapolate long-term protection from the 4
years of UK effectiveness data, and consistent with prevail-
ing assumptions in infectious disease transmission mod-
els [20], we assumed that waning of vaccine protection is
exponential (VE(t) = se-wt). The coefficients for the equa-
tion were estimated using the least squares method from
data corresponding to adolescents vaccinated between 11
and 16 years of age. The mean duration of direct protec-
tion against meningococcal infection under these
assumptions is 30.1 years (Figure 2).
For estimates of protection against carriage, necessary for
calculation of the indirect effects of vaccination, we con-
servatively assumed that protection waned at twice the
rate of protection against disease (w = 0.0648 for protec-
tion against carriage in the base case, and 0.1296 in sensi-
tivity analyses).
Indirect effects of vaccination
The meningococcal C vaccination campaign in the UK
[11], demonstrated that benefits accrue not only to vacci-
nated individuals, but also to the entire population. These
are referred to as the "indirect" effects of vaccination (i.e.,
the reduction in the risk of contracting the disease due to
fewer individuals transmitting it, or "herd" immunity). In
order to capture these effects, an assumption was made
that vaccinating individuals with a conjugate vaccine
decreases the probability that they are carriers and can
transmit the disease. Consistent with a recent epidemio-
logical model of the impact of meningococcal vaccination
in the UK [20], individuals in the same age group were
assumed to mix more frequently than individuals across
age groups. Inputs were calibrated to reproduce the out-
come observed in the UK that with vaccination of 81% of
Table 4: Relative risk of infection over time given presence of an 
index case
Setting 0 to 6 days 7 to 30 days 31 to 365 days
Household 1200 150 8
Primary School 60 13 1
High School 160 7 1
College 1.8 1.5 1
Table 3: Coefficients for Weibull functions† used to estimate rate of invasive disease
Group B Group C Group Y <44 yrs Group Y >44 yrs Group A Group W-135 Other Groups
P1 2.2044 0.8692 0.8490 0.000003 0.0107 0.2943 0.2301
P2 -0.7285 -0.4598 -0.5234 2.800 -0.3741 -0.3741 -0.3741
†PA g e P
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Page 11 of 12
(page number not for citation purposes)
individuals under the age of 20 years, disease incidence
fell by 67% in unvaccinated individuals in the same age
group and 35% in adults [11]. Conservatively, the indirect
effects are assumed to decrease at rates twice that of direct
ones. Specifically, indirect effects are included in the
model through a factor reducing age-specific rates of inva-
sive disease. These factors are calculated based on the
reduction of carriers in the population resulting from vac-
cination and their contribution to the transmission of the
disease within age group i. Formally:
where h0 is the parameter measuring the overall impact of
vaccination on the reduction of attack rates, aij the ele-
ments of the matrix representing the relative impact of age
groups j on the transmission of disease to individuals
belonging to age group i, vi the proportion of carriers pro-
tected by vaccination in age group i, ci, the rate of carriers
in age group i and pi the number of individuals in age
group i.
The vi values depend on the vaccination strategy analyzed
and pi on the population considered. If one assumes that
the relative propensity to be a carrier according to age
remains stable when vaccination is implemented, measur-
ing indirect effects simply requires the identification of
the values associated to h0 and aij. This was accomplished
by using data from the UK [11] on the age-specific reduc-
tion in incidence among non-vaccinated individuals and
2001 statistics for the size and age distribution of the UK
population. Six age groups were considered: under three
years, four to six years, seven to 12 years, 13 to 16 years,
17 to 19 years, and, 20 or greater years of age. The carriage
rates considered were based on published data [47].
Development of the matrix required assuming no age-
dependence of aij to avoid too many unknowns. These val-
ues were fixed at 1 (specifically ∀ i ≠ j aij = 1, a66 = 1). The
remaining values of aij and h0 were therefore calculated to
match the UK data assuming a vaccine efficacy of 90%: a11
= 80.4, a22 = 40.2, a33 = 2.4, a44 = 6.8, a55 = 6.3, h0 = 2.55.
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